Most frequent complaints reported(multiple complaints per patient are possible)

Adverse effect may be due to disease and/or other underlying condition and medication/treatment may not be causative factor




DRUG RATING DETAILS (RANK BASED ON RATINGS OF SIMILAR DRUGS; SEE TABLE AT BOTTOM)


Drug Brand Name Thiola
Drug Substance/Generic Name tiopronin
Number of Patients Complaining 716
Serious Reactions to Substance 121
Non Serious Reactions to Substance 602
Substance Not Effective Complaints 115
At-Ray Ratio (NSR/SR); Safety indicator, higher is safer 5.00
PP Ratio (Patients Complaining/Not Effective), higher is more effective 6.23
Drug Rating = PP Ratio* At-Ray Ratio 31.25

Summary (from Wikipedia)




Indications and Usage (from FDA label)


INDICATIONS AND USAGE THIOLA® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine. Cystine stones typically occur in approximately 10,000 persons in the United States who are homozygous for cystinuria. These persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). In addition, they show varying intestinal transport defects for these same amino acids. The stone formation is the result of poor aqueous solubility of cystine. Since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. Thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. Cystine solubility in urine is pH-dependent, and ranges from 170-300 mg/liter at pH 5, 190-400 mg/liter at pH 7 and 220-500 mg/liter at pH 7.5. The goal of therapy is to reduce urinary cystine concentration below its solubility limit. It may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. Unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). In such patients, d-penicillamine has been used as an additional therapy. Like THIOLA™, dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine. However, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. THIOLA® may have a particular therapeutic role in such patients.

Copyright for images below belongs to manufacturer mentioned in label, presented for information only


Other urologicals
(13) Similar Drugs to Thiola ; Comparison Table Below
(Best drugs have high rating/ranking,high safety ratio and high effectivity ratio)
Brand Name (Click for details) Active Ingredient Drug ATC Class Price Found (US $) OVERALL
Drug Rating

Thiola FORUM: Comments, Support, Doubts? Please sign on to disqus(www.disqus.com) and post below

Forum